Skip to content
ONIX logo blue
  • HOME
  • ABOUT
    • TEAM
  • SERVICES
    • eCTD Submission Management Services
    • Regulatory Advisory Services
    • eCTD MS Word & PDF Formatting
    • eCTD Template Automation
    • Regulatory Affairs Services
    • eSUBMISSION – Expertise
  • eCTD NEWS
    • Testimonials
Menu
  • HOME
  • ABOUT
    • TEAM
  • SERVICES
    • eCTD Submission Management Services
    • Regulatory Advisory Services
    • eCTD MS Word & PDF Formatting
    • eCTD Template Automation
    • Regulatory Affairs Services
    • eSUBMISSION – Expertise
  • eCTD NEWS
    • Testimonials
Contact
ONIX logo blue
Contact
  • HOME
  • ABOUT
    • TEAM
  • SERVICES
    • eCTD Submission Management Services
    • Regulatory Advisory Services
    • eCTD MS Word & PDF Formatting
    • eCTD Template Automation
    • Regulatory Affairs Services
    • eSUBMISSION – Expertise
  • eCTD NEWS
    • Testimonials
Menu
  • HOME
  • ABOUT
    • TEAM
  • SERVICES
    • eCTD Submission Management Services
    • Regulatory Advisory Services
    • eCTD MS Word & PDF Formatting
    • eCTD Template Automation
    • Regulatory Affairs Services
    • eSUBMISSION – Expertise
  • eCTD NEWS
    • Testimonials
etch weekly update image

eCTD Industry Update (13th July 2023)

July 13, 2023
/
onix

EMA

  • PRIME: priority medicines (updated)
  • Other: European Medicines Agency guidance for applicants seeking access to PRIME scheme (updated)
  • Referrals document: Nitrosamines EMEA-H-A5(3)-1490 - Questions and answers for marketing authorisation holders / applicants on the CHMP Opinion for the Article 5(3) of Regulation (EC) No 726/2004 referral on nitrosamine impurities in human medicinal products (updated)
  • Regulatory and procedural guideline: European Medicines Agency post-authorisation procedural advice for users of the centralised procedure (Clean Version / Tracked Version) (updated)
  • Risk management plans (RMP) in post-authorisation phase: questions and answers (updated)
  • Type-II variations: questions and answers (updated)
  • Extensions of marketing authorisations: questions and answers (updated)
  • Regulatory and procedural guideline: European Medicines Agency pre-authorisation procedural advice for users of the centralised procedure (Clean Version / Tracked Version) (updated)
  • Pre-authorisation guidance (updated)
  • Other: Chapter 3.II: XEVPRM user guidance of the Detailed guidance on the electronic submission of information on medicinal products for human use by marketing authorisation holders to the EMA (updated)

eSubmissions (eCTD)

  • Updated draft eCTD v4.0 implementation timeline for EU now available

An updated draft timeline for the implementation of eCTD v4.0 in the EU is now available on the eCTD v4.0 page here.

  • A new version of the PSUR Repository NCA UI is now available

An updated version of the PSUR Repository NCA UI is now available. The new version of the PSUR Repository NCA User Interface provides a technical update only. Following the update, the PSUR Repository NCA UI has slightly different look and feel, however, there are no changes to the features and functionality of the system.

User Guidance and the Release Notes were updated and they can be found in the “User Documents” section of the page.

MHRA

  • Regulating medical devices in the UK - 1 July 2023 – Guidance
  • Register medical devices to place on the market 6 July 2023 - Guidance

Health Canada 

  • Master file application form [2023-06-26]
  • Updated: Guidance on procedures and administrative requirements for master files [2023-06-26]
PreveCTD Industry Update (4th July 2023)
eCTD Industry Update (17th July 2023)Next
  • HOME
  • ABOUT
  • SERVICES
  • eCTD NEWS
  • CONTACT
Menu
  • HOME
  • ABOUT
  • SERVICES
  • eCTD NEWS
  • CONTACT
  • HOME
  • ABOUT
  • SERVICES
  • eCTD NEWS
  • CONTACT
Menu
  • HOME
  • ABOUT
  • SERVICES
  • eCTD NEWS
  • CONTACT
Twitter Linkedin

© Copyright 2025

ONIX Life Sciences Ltd, 59-60 Thames Street, Windsor, Berkshire, SL4 1TX.

ONIX Life Sciences Inc, 500 Delaware Ave, Ste 1 #1960, Wilmington, DE 19899, USA

ONIX Life Sciences Ltd, Salarpuria Sanctity, Kasavanahalli, Sarjapur Road, Bangalore 560035 India

+44 (0) 1753 257 904 | info@onixls.com | www.onixls.com

Privacy Policy